Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
USE OF RECOMBINANT CXCL16 AND INTERFERON-γ IN PREPARATION OF DRUG FOR INHIBITING PROLIFERATION OF DIFFUSE LARGE B-CELL LYMPHOMA CELLS
Document Type and Number:
WIPO Patent Application WO/2019/006803
Kind Code:
A1
Abstract:
Disclosed is the use of a recombinant CXCL16 and interferon-γ in the preparation of a drug for inhibiting the proliferation of diffuse large B-cell lymphoma cells. In particular, the recombinant CXCL16 is used in combination with the interferon-γ in the preparation of a drug for inhibiting the proliferation of diffuse large B-cell lymphoma cells.

Inventors:
QIU BO (CN)
LIU FANG (CN)
Application Number:
PCT/CN2017/095354
Publication Date:
January 10, 2019
Filing Date:
July 31, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
QIU BO (CN)
LIU FANG (CN)
International Classes:
A61K38/19; A61P35/00
Other References:
L DENG ET AL.: "CXCR6/CXCL16 Functions As a Regulator in Metastasis and Progression of Cancer", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1806, no. 1, 1 August 2010 (2010-08-01), pages 42 - 49, XP055558749
DICK WÅGSÄTER ET AL.: "The Chemokine and Scavenger Receptor CXCL16/SR-PSOX is Expressed in Human Vascular Smooth Muscle Cells And Is Induced By Interferon y", BIOCHEMICAL AND BIOPHYSICAL COMMUNICATIONS, vol. 325, no. 4, 11 November 2004 (2004-11-11), pages 1187 - 1193, XP004649730
DM WUTTGE ET AL.: "CXCL16/SR-PSOX Is an Interferon-gamma-Regulated Chemokine and Scavenger Receptor Expressed in Atherosclerotic Lesions", ARTERIOSCLER THROMB VASE BIOL., vol. 24, no. 4, 1 April 2004 (2004-04-01), pages 750 - 755, XP055558750
Attorney, Agent or Firm:
SCIHEAD PATENT AGENT CO., LTD (CN)
Download PDF: